Predicting Tumor Sensitivity to Cyclophosphamide
Author Information
Author(s): F.Y.F. Lee, D.J. Flannery, D.W. Siemann
Primary Institution: University of Rochester Cancer Center
Hypothesis
Can a glutathione-targeted assay predict patient tumor response to cyclophosphamide?
Conclusion
The study found that a significant reduction in tumor cell reproductive capacity is linked to substantial depletion of cellular glutathione, indicating that glutathione levels can predict sensitivity to cyclophosphamide.
Supporting Evidence
- A significant correlation was found between glutathione depletion and clonogenic cell survival (r=0.90-0.91).
- Cells with GSH depletion to 40% of initial content showed approximately 1% clonogenic survival.
- Different tumor cell lines exhibited a wide range of sensitivities to 4-OOH-CP.
Takeaway
This study shows that measuring glutathione levels in tumor cells can help doctors figure out how well a cancer treatment will work.
Methodology
The study used a panel of 19 human and 3 murine tumor cell lines to evaluate the relationship between glutathione depletion and chemosensitivity to 4-OOH-CP.
Limitations
The study does not confirm whether high glutathione levels alone cause treatment failure in patients.
Participant Demographics
The study included various human tumor cell lines from ovarian, lung, and squamous cell carcinomas.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% confidence limits = 3 x 10-5 - 1.6 x 10-2
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website